Abiopharma

NASCENT BIOTECH INC. (NBIO)

Symbol	NBIO
Name	NASCENT BIOTECH INC.
Sector	UNDEFINED
Region	North America
Industry	-
Address	33408 United States FL 631 US Hwy 1 Suite 407
Telephone	+1 (612) 961-5656
Fax	—
Email	—
Website	http://www.nascentbiotech.com
Incorporation	US
Incorporated On	2008
Employees	—
Fiscal Year	3/31
Public Since	—
Exchanges	OTC
Auditor	Fruci & Associates II, PLLC;
Audit Status	AUDITED
Reporting Status	Dark: Alternative Reporting Standard
CIK	0001622057
Description	Nascent Biotech is a clinical stage bio-pharmaceutical company whose Investigational New Drug (IND) application was cleared in December 2018, by the US Food and Drug Administration (FDA),and has completed Phase I human trials on brain cancer patients with its monoclonal antibody product Pritumumab. The Company has been cleared by the FDA to begin phase 2 clinical trials. The objective of the Phase 2 human clinical trial is to assess potential efficacy in reducing the size or eliminating brain tumors, both primary and metastatic. Nascent is focused on developing Pritumumab for the treatment of patients with brain cancer malignancies such as Gliomas and Astrocytomas. Current therapeutic strategies include chemotherapy, radiation and/or surgery. There exists a need to develop safer more effective drugs and treatment options for this deadly cancer. Additional info from OTC: Nascent Biotech is a clinical stage bio-pharmaceutical company whose Investigational New Drug (IND) application was cleared in December 2018, by the US Food and Drug Administration (FDA),and has completed Phase I human trials on brain cancer patients with its monoclonal antibody product Pritumumab. The Company has been cleared by the FDA to begin phase 2 clinical trials. The objective of the Phase 2 human clinical trial is to assess potential efficacy in reducing the size or eliminating brain tumors, both primary and metastatic. Nascent is focused on developing Pritumumab for the treatment of patients with brain cancer malignancies such as Gliomas and Astrocytomas. Current therapeutic strategies include chemotherapy, radiation and/or surgery. There exists a need to develop safer more effective drugs and treatment options for this deadly cancer.

2025-04-17 12:13

Letter to Shareholders from Sean Carrick

2025-02-11 13:00

Message From Senior Management

2024-11-15 19:29

New Form NT 10-Q - Nascent Biotech Inc. Filed: 2024-11-15 AccNo: 0001477932-24-007303 Size: 34 KB

2024-09-10 17:21

VIDEO: Nascent Biotech CEO Sean Carrick at the Emerging Grown Conference

2024-08-30 12:10

OTCQB symbol attribute type Security_Name was changed. Previous value: -. New value: NASCENT BIOTECH INC.

2024-08-27 08:16

OTCQX U.S. Premier symbol attribute type Security_Name was changed. Previous value: CONSUMERS BANCORP INC. New value: NASCENT BIOTECH INC.

2024-07-02 12:51

HOLDEN LOWELL THOMAS 🟢 acquired 96.0K shares of Nascent Biotech Inc. (NBIO) at $0.09 Transaction Date: Jun 30, 2024 | Filing ID: 004031

2024-07-02 12:51

Karas Douglas John 🟢 acquired 50.0K shares of Nascent Biotech Inc. (NBIO) at $0.10 Transaction Date: Jun 30, 2024 | Filing ID: 004032

2024-07-02 12:51

Carrick Sean 🟢 acquired 192.0K shares of Nascent Biotech Inc. (NBIO) at $0.09 Transaction Date: Jun 30, 2024 | Filing ID: 004030

2024-07-01 21:31

New Form 10-K - Nascent Biotech Inc. Filed: 2024-07-01 AccNo: 0001477932-24-004020 Size: 4 MB